Cargando…
Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide
Pomalidomide, a derivative of thalidomide, is an effective treatment for multiple myeloma. The drug exerts its effects through CRBN, a component of the E3 ubiquitin ligase complex CRL4(CRBN). To search for novel factors involved in the anti-cancer activity of pomalidomide, we performed a genome-wide...
Autores principales: | Tateno, Shumpei, Iida, Midori, Fujii, Satoshi, Suwa, Tetsufumi, Katayama, Miki, Tokuyama, Haruka, Yamamoto, Junichi, Ito, Takumi, Sakamoto, Satoshi, Handa, Hiroshi, Yamaguchi, Yuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055313/ https://www.ncbi.nlm.nih.gov/pubmed/32132601 http://dx.doi.org/10.1038/s41598-020-61027-w |
Ejemplares similares
-
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
por: Shimizu, Nobuyuki, et al.
Publicado: (2021) -
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
por: Bjorklund, C C, et al.
Publicado: (2015) -
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019) -
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014) -
Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)